A major downgrade, a billion-dollar pipeline gamble, and a patent war--Exelixis investors brace for a wild ride.

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Exelixis (EXEL – Research Report), with a price target of ...

Truist Securities increased its price target for Exelixis (NASDAQ:EXEL) shares to $43.00, up from the previous target of $42.00, while reaffirming a Buy rating on the stock. The new target represents ...

Stifel analysts maintained a Hold rating with a $30.00 price target on Exelixis stock (NASDAQ:EXEL), currently trading at $33.32 with a market capitalization of $9.5 billion. According to InvestingPro ...

Park Avenue Securities LLC acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and ...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good ...

On Friday, Exelixis Inc (EXEL) stock saw a decline, ending the day at $32.38 which represents a decrease of $-1.75 or -5.13% from the prior close of $34.13. The stock opened at $33.49 and touched a ...

EXEL designs advanced medicines and regimens to battle cancer. Its product portfolio focuses on an expanding range of tumors, ...

Exelixis (NASDAQ:EXEL – Get Free Report) had its price target raised by research analysts at Truist Financial from $38.00 to ...

Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $34.13 which represents a slight increase of $1.25 or 3.80% from the prior close of $32.88. The stock opened at $33 and touched a low ...